Cited by 900Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsMedicinal Plants and Neuroprotection

The DOI matches its Crossref record; 61 of the 62 references it cites were found in a registry or an index.

Global estimates on the number of persons across the Alzheimer's disease continuum

Open access

Gustavsson, Anders, Norton, Nicholas, Fast, Thomas, Frölich, Lutz, Georges, Jean, Holzapfel, Drew, Kirabali, Tunahan, Krolak‐Salmon, Pierre, Rossini, Paolo M., Ferretti, Maria Teresa, Lanman, Lydia, Chadha, Antonella Santuccione, van der Flier, Wiesje M.·2023·Alzheimer's & Dementia

DOI 10.1002/alz.12694

Open this paper in CoChat — free account Open PDF

Abstract

Introduction: Global estimates on numbers of persons in early stages of Alzheimer's disease (AD), including prodromal and preclinical, are lacking, yet are needed to inform policy decisions on preventive measures and planning for future therapies targeting AD pathology. Methods: We synthesized the literature on prevalence across the AD continuum and derived a model estimating the number of persons, stratified by 5‐year age groups, sex, and disease stage (AD dementia, prodromal AD, and preclinical AD). Results: The global number of persons with AD dementia, prodromal AD, and preclinical AD were estimated at 32, 69, and 315 million, respectively. Together they constituted 416 million across the AD continuum, or 22% of all persons aged 50 and above. Discussion: Considering predementia stages, the number of persons with AD is much larger than conveyed in available literature. Our estimates are uncertain, especially for predementia stages in low‐ and middle‐income regions where biomarker studies are missing.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1002/alz.12694

Cites

61 of 61 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

1 retracted

Dementia prevention, intervention, and care: 2020 report of the Lancet Commission
Livingston, G., Huntley, J., Sommerlad, A., Ames, D., Ballard, C., Banerjee, S., Brayne, C., Burns, A., Cohen-Mansfield, J., Cooper, C., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30367-6 · Cited by 10,430
Retracted
Clinical diagnosis of Alzheimer's disease: Report of the NINCDS‐ADRDA Work Group* under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019
Vos, T., Lim, S. S., Abbafati, C., Abbas, K. M., Abbasi, M., Abbasifard, M., Abbasi-Kangevari, M., Abbastabar, H., Abd-Allah, F., Abdelalim, A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30925-9 · Cited by 19,358
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
Mild cognitive impairment as a diagnostic entity
Petersen, R. C. (2004) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2004.01388.x · Cited by 7,864
Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease
Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155
Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019
Nichols, E., Steinmetz, J. D., Vollset, S. E., Fukutaki, K., Chalek, J., Abd-Allah, F., Abdoli, A., Abualhasan, A., Abu-Gharbieh, E., Akram, T. T., et al. (2022) · The Lancet Public Health · doi:10.1016/s2468-2667(21)00249-8 · Cited by 5,575
Mild cognitive impairment – Beyond controversies, towards a consensus: Report of the International Working Group on Mild Cognitive Impairment.
Winblad, B., Palmer, K., Kivipelto, M., Jelic, V., Fratiglioni, L., Wahlund, L. ‐., Nordberg, A., Bäckman, L., Albert, M., Almkvist, O., et al. (2004) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2004.01380.x · Cited by 4,946
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria
Dubois, B., Feldman, H. H., Jacova, C., DeKosky, S. T., Barberger-Gateau, P., Cummings, J., Delacourte, A., Galasko, D., Gauthier, S., Jicha, G., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70178-3 · Cited by 4,411
A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial
Ngandu, T., Lehtisalo, J., Solomon, A., Levälahti, E., Ahtiluoto, S., Antikainen, R., Bäckman, L., Hänninen, T., Jula, A., Laatikainen, T., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60461-5 · Cited by 3,689

Show all 62 references

Research works printed but not linked: 3

WHO, 2019, Risk reduction of cognitive decline and dementia: WHO guidelines, Geneva: World Health Organization
American Psychiatric Association Diagnostic and statistical manual of mental disorders.2000(4th edition).
WHO, 2021, Global status report on the public health response to dementia, Geneva: World Health Organization

Sorted by citations

2023 Alzheimer's disease facts and figures
(2023) · Alzheimer's & Dementia · doi:10.1002/alz.13016 · Cited by 3,212
2024 Alzheimer's disease facts and figures
(2024) · Alzheimer's & Dementia · doi:10.1002/alz.13809 · Cited by 2,536
2025 Alzheimer's disease facts and figures
(2025) · Alzheimer s & Dementia · doi:10.1002/alz.70235 · Cited by 642
Alzheimer’s disease drug development pipeline: 2023
Cummings, J., Zhou, Y., Lee, G., Zhong, K., Fonseca, J., & Cheng, F. (2023) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1002/trc2.12385 · Cited by 477
The NLRP3 inflammasome: contributions to inflammation-related diseases
Chen, Y., Ye, X., Escames, G., Lei, W., Zhang, X., Li, M., Jing, T., Yao, Y., Qiu, Z., Wang, Z., et al. (2023) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-023-00462-9 · Cited by 492
Alzheimer Disease as a Clinical-Biological Construct—An International Working Group Recommendation
Dubois, B., Villain, N., Schneider, L., Fox, N., Campbell, N., Galasko, D., Kivipelto, M., Jessen, F., Hanseeuw, B., Boada, M., et al. (2024) · JAMA Neurology · doi:10.1001/jamaneurol.2024.3770 · Cited by 426
Self-citation
Towards a future where Alzheimer’s disease pathology is stopped before the onset of dementia
van der Flier, W. M., de Vugt, M. E., Smets, E. M. A., Blom, M., & Teunissen, C. E. (2023) · Nature Aging · doi:10.1038/s43587-023-00404-2 · Cited by 220
Clinical diagnostic utility of transcranial magnetic stimulation in neurological disorders. Updated report of an IFCN committee
Vucic, S., Chen, K.-H. S., Kiernan, M. C., Hallett, M., Benninger, D. H., Lazzaro, V. D., Rossini, P. M., Benussi, A., Berardelli, A., Currà, A., et al. (2023) · Clinical Neurophysiology · doi:10.1016/j.clinph.2023.03.010 · Cited by 238
Self-citation
Neurotransmitter systems in the etiology of major neurological disorders: Emerging insights and therapeutic implications
Nimgampalle, M., Chakravarthy, H., Sharma, S., Shree, S., Bhat, A. R., Pradeepkiran, J. A., & Devanathan, V. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.101994 · Cited by 207
Cell type‐specific roles of APOE4 in Alzheimer disease
Blumenfeld, J., Yip, O., Kim, M. J., & Huang, Y. (2024) · Nature Reviews Neuroscience · doi:10.1038/s41583-023-00776-9 · Cited by 202
Dementia prevention in memory clinics: recommendations from the European task force for brain health services
Frisoni, G. B., Altomare, D., Ribaldi, F., Villain, N., Brayne, C., Mukadam, N., Abramowicz, M. J., Barkhof, F., Berthier, M. L., Bieler-Aeschlimann, M., et al. (2023) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2022.100576 · Cited by 187
Self-citation
Burden of Illness in People with Alzheimer's Disease: A Systematic Review of Epidemiology, Comorbidities and Mortality
Lanctôt, K. L., Hahn‐Pedersen, J. H., Eichinger, C. S., Freeman, C. S., Clark, A., Tarazona, L. R. S., & Cummings, J. L. (2023) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2023.61 · Cited by 163
New landscape of the diagnosis of Alzheimer’s disease
Frisoni, G. B., Hansson, O., Nichols, E., Garibotto, V., Schindler, S. E., van der Flier, W. M., Jessen, F., Villain, N., Arenaza-Urquijo, E. M., Crivelli, L., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01294-2 · Cited by 143
Pathological phenotypes of astrocytes in Alzheimer’s disease
Kim, J., Yoo, I. D., Lim, J., & Moon, J. (2024) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-01148-0 · Cited by 154
Vitamin D: Evidence-Based Health Benefits and Recommendations for Population Guidelines
Grant, W. B., Wimalawansa, S. J., Płudowski, P., & Cheng, R. Z. (2025) · Nutrients · doi:10.3390/nu17020277 · Cited by 156
The affordability of lecanemab, an amyloid-targeting therapy for Alzheimer's disease: an EADC-EC viewpoint
Jönsson, L., Wimo, A., Handels, R., Johansson, G., Boada, M., Engelborghs, S., Frölich, L., Jessen, F., Kehoe, P. G., Kramberger, M., et al. (2023) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2023.100657 · Cited by 129
Self-citation
Brain clocks capture diversity and disparities in aging and dementia across geographically diverse populations
Moguilner, S., Baez, S., Hernandez, H., Migeot, J., Legaz, A., Gonzalez-Gomez, R., Farina, F. R., Prado, P., Cuadros, J., Tagliazucchi, E., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03209-x · Cited by 128
Physical exercise, cognition, and brain health in aging
Silva, N. C. B. S., Barha, C. K., Erickson, K. I., Kramer, A. F., & Liu-Ambrose, T. Y. L. (2024) · Trends in Neurosciences · doi:10.1016/j.tins.2024.04.004 · Cited by 130
Targeted Dephosphorylation of Tau by Phosphorylation Targeting Chimeras (PhosTACs) as a Therapeutic Modality
Hu, Z., Chen, P.-H., Li, W., Douglas, T., Hines, J., Liu, Y., & Crews, C. M. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.2c11706 · Cited by 98
Multi‐Target Drug Design in Alzheimer's Disease Treatment: Emerging Technologies, Advantages, Challenges, and Limitations
Hossain, M. S., & Hussain, M. H. (2025) · Pharmacology Research & Perspectives · doi:10.1002/prp2.70131 · Cited by 105
The Expanding Burden of Neurodegenerative Diseases: An Unmet Medical and Social Need
Wang, S., Jiang, Y., Yang, A., Meng, F., & Zhang, J. (2024) · Aging and Disease · doi:10.14336/ad.2024.1071 · Cited by 115
Sex and gender considerations in Alzheimer’s disease: The Women’s Brain Project contribution
Castro‐Aldrete, L., Moser, M. V., Putignano, G., Ferretti, M. T., Dimech, A. S., & Chadha, A. S. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1105620 · Cited by 87
Self-citation
The Role of Brain-Derived Neurotrophic Factor (BDNF) in Diagnosis and Treatment of Epilepsy, Depression, Schizophrenia, Anorexia Nervosa and Alzheimer’s Disease as Highly Drug-Resistant Diseases: A Narrative Review
Gliwińska, A., Czubilińska-Łada, J., Więckiewicz, G., Świętochowska, E., Badeński, A., Dworak, M., & Szczepańska, M. (2023) · Brain Sciences · doi:10.3390/brainsci13020163 · Cited by 85
Amyloid-β and Phosphorylated Tau are the Key Biomarkers and Predictors of Alzheimer’s Disease
Pradeepkiran, J. A., Baig, J., Islam, M. A., Kshirsagar, S., & Reddy, P. H. (2024) · Aging and Disease · doi:10.14336/ad.2024.0286 · Cited by 87
Diet’s Role in Modifying Risk of Alzheimer’s Disease: History and Present Understanding
Grant, W. B., & Blake, S. M. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-230418 · Cited by 82
Modified titration of donanemab reduces ARIA risk and maintains amyloid reduction
Wang, H., Nery, E. S. M., Ardayfio, P. A., Khanna, R., Svaldi, D. O., Gueorguieva, I., Shcherbinin, S., Andersen, S. W., Hauck, P. M., Engle, S. E., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70062 · Cited by 77
Quercetin-functionalized nanomaterials: Innovative therapeutic avenues for Alzheimer's disease management
Pei, J., Kumarasamy, R. V., Jayaraman, S., Kanniappan, G. V., Long, Q., & Palanisamy, C. P. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102665 · Cited by 72
Irisin: A Multifaceted Hormone Bridging Exercise and Disease Pathophysiology
Paoletti, I., & Coccurello, R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252413480 · Cited by 81
Smartwatch- and smartphone-based remote assessment of brain health and detection of mild cognitive impairment
Butler, P. M., Yang, J. F., Brown, R. Z., Hobbs, M., Becker, A., Penalver-Andres, J. A., Syz, P., Muller, S., Cosne, G., Juraver, A., et al. (2025) · Nature Medicine · doi:10.1038/s41591-024-03475-9 · Cited by 66
Nanomedicine in the Management of Alzheimer’s Disease: State-of-the-Art
Ullah, S. N. M. N., Afzal, O., Altamimi, A. S. A., Ather, H., Sultana, S., Almalki, W. H., Bharti, P., Sahoo, A., Dwivedi, K., Khan, G., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11061752 · Cited by 68
Latest advances in dual inhibitors of acetylcholinesterase and monoamine oxidase B against Alzheimer’s disease
Zou, D., Liu, R., Lv, Y., Guo, J., Zhang, C., & Xie, Y. (2023) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2023.2270781 · Cited by 60
Hydrogen sulfide signalling in neurodegenerative diseases
Tripathi, S. J., Chakraborty, S., Miller, E., Pieper, A. A., & Paul, B. D. (2023) · British Journal of Pharmacology · doi:10.1111/bph.16170 · Cited by 61
Effect of renal function on the diagnostic performance of plasma biomarkers for Alzheimer’s disease
Zhang, B., Zhang, C., Wang, Y., Chen, L., Qiao, Y., Wang, Y., Peng, D., & Initiative, A. D. N. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1150510 · Cited by 58
AI-powered integration of multimodal imaging in precision medicine for neuropsychiatric disorders
Huang, W., & Shu, N. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102132 · Cited by 69
Time‐restricted feeding mitigates Alzheimer's disease‐associated cognitive impairments via a B. pseudolongum ‐propionic acid‐FFAR3 axis
Zhao, Y., Jia, M., Ding, C., Bao, B., Li, H., Ma, J., Dong, W., Gao, R., Chen, X., Chen, J., et al. (2025) · iMeta · doi:10.1002/imt2.70006 · Cited by 57
Tau PET positivity in individuals with and without cognitive impairment varies with age, amyloid-β status, APOE genotype and sex
Ossenkoppele, R., Coomans, E. M., Apostolova, L. G., Baker, S. L., Barthel, H., Beach, T. G., Benzinger, T. L. S., Betthauser, T. J., Bischof, G. N., Bottlaender, M., et al. (2025) · Nature Neuroscience · doi:10.1038/s41593-025-02000-6 · Cited by 60
Incidence and prevalence of Alzheimer’s disease in China: a systematic review and meta-analysis
Ji, Q., Chen, J., Li, Y., Tao, E., & Zhan, Y. (2024) · European Journal of Epidemiology · doi:10.1007/s10654-024-01144-2 · Cited by 59
Music Engagement as a Source of Cognitive Reserve
Wolff, L., Quan, Y., Perry, G., & Thompson, W. F. (2023) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/15333175231214833 · Cited by 53
Prevalence of Alzheimer’s disease pathology in the community
Aarsland, D., Sunde, A. L., Tovar, D., Leuzy, A., Fladby, T., Zetterberg, H., Blennow, K., Tan, K., Santis, G. D., Yakoub, Y., et al. (2025) · Nature · doi:10.1038/s41586-025-09841-y · Cited by 75
The association of glucose metabolism measures and diabetes status with Alzheimer’s disease biomarkers of amyloid and tau: A systematic review and meta-analysis
van Gils, V., Rizzo, M., Côté, J., Viechtbauer, W., Fanelli, G., Salas‐Salvadó, J., Wimberley, T., Bulló, M., Fernández‐Aranda, F., Dalsgaard, S., et al. (2024) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2024.105604 · Cited by 50
The ATN Framework—Moving Preclinical Alzheimer Disease to Clinical Relevance
van der Flier, W. M., & Scheltens, P. (2022) · JAMA Neurology · doi:10.1001/jamaneurol.2022.2967 · Cited by 50
Alzheimer's disease: The role of proteins in formation, mechanisms, and new therapeutic approaches
Gholami, A. (2023) · Neuroscience Letters · doi:10.1016/j.neulet.2023.137532 · Cited by 52
Current Anti-Amyloid-β Therapy for Alzheimer’s Disease Treatment: From Clinical Research to Nanomedicine
Zhao, Z., Liu, Y., Ruan, S., & Hu, Y. (2023) · International Journal of Nanomedicine · doi:10.2147/ijn.s444115 · Cited by 49
The Role of IL-6 in Neurodegenerative Disorders
Shan, C., Zhang, C., & Zhang, C. (2024) · Neurochemical Research · doi:10.1007/s11064-023-04085-6 · Cited by 52
The evolving landscape of Alzheimer’s disease therapy: From Aβ to tau
Courade, J., Zetterberg, H., Höglinger, G. U., & Dewachter, I. (2025) · Cell · doi:10.1016/j.cell.2025.11.033 · Cited by 57
The role of the CD8+ T cell compartment in ageing and neurodegenerative disorders
Terrabuio, E., Zenaro, E., & Constantin, G. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1233870 · Cited by 51
A probe for NIR-II imaging and multimodal analysis of early Alzheimer’s disease by targeting CTGF
Lu, C., Meng, C., Li, Y., Yuan, J., Ren, X., Gao, L., Su, D., Cao, K., Cui, M., Yuan, Q., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-49409-4 · Cited by 48
Components of effective exergame-based training to improve cognitive functioning in middle-aged to older adults – A systematic review and meta-analysis
Manser, P., Herold, F., & de Bruin, E. D. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102385 · Cited by 52
Microglia and gut microbiota: A double-edged sword in Alzheimer's disease
Bano, N., Khan, S., Ahamad, S., Kanshana, J. S., Dar, N. J., Khan, S. J., Nazir, A., & Bhat, S. A. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102515 · Cited by 50
Engineered Exosomes as Smart Drug Carriers: Overcoming Biological Barriers in CNS and Cancer Therapy
Premchandani, T., Tatode, A., Taksande, J., Umekar, M. J., Qutub, M., Hussain, U., & Singanwad, P. (2025) · Drugs and Drug Candidates · doi:10.3390/ddc4020019 · Cited by 54
Gut microbiome and Alzheimer’s disease: What we know and what remains to be explored
Kapoor, B., Biswas, P., Gulati, M., Rani, P., & Gupta, R. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102570 · Cited by 46
Rg1 improves Alzheimer's disease by regulating mitochondrial dynamics mediated by the AMPK/Drp1 signaling pathway
Zhang, Y., Liu, S., Cao, D., Zhao, M., Lu, H., & Wang, P. (2024) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2024.119285 · Cited by 48
Stereo-seq of the prefrontal cortex in aging and Alzheimer’s disease
Gong, Y., Haeri, M., Zhang, X., Li, Y., Liu, A., Wu, D., Zhang, Q., Jazwinski, S. M., Zhou, X., Wang, X., et al. (2025) · Nature Communications · doi:10.1038/s41467-024-54715-y · Cited by 52
Age-Related Cognitive Decline, Focus on Microbiome: A Systematic Review and Meta-Analysis
Coradduzza, D., Sedda, S., Cruciani, S., Miglio, M. R. D., Ventura, C., Nivoli, A., & Maioli, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241813680 · Cited by 45
The potential role of gut microbiota-derived metabolites as regulators of metabolic syndrome-associated mitochondrial and endolysosomal dysfunction in Alzheimer’s disease
Jung, Y. H., Chae, C. W., & Han, H. J. (2024) · Experimental & Molecular Medicine · doi:10.1038/s12276-024-01282-3 · Cited by 47
Advancements in the Application of Nanomedicine in Alzheimer’s Disease: A Therapeutic Perspective
Puranik, N., Yadav, D., & Song, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241814044 · Cited by 45
Newer Therapeutic Approaches in Treating Alzheimer’s Disease: A Comprehensive Review
Sree, R. R., Kalyan, M., Anand, N., Mani, S., Gorantla, V. R., Sakharkar, M. K., Song, B., & Chidambaram, S. B. (2025) · ACS Omega · doi:10.1021/acsomega.4c05527 · Cited by 45
Olfactory deficit: a potential functional marker across the Alzheimer’s disease continuum
Liu, D., Lu, J., Wei, L., Yao, M., Yang, H., Lv, P., Wang, H., Zhu, Y., Zhu, Z., Zhang, X., et al. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1309482 · Cited by 41
Roles of TREM2 in the Pathological Mechanism and the Therapeutic Strategies of Alzheimer's Disease
Lin, M., Yu, J., Zhang, W., Lao, F., & Huang, H. (2024) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2024.164 · Cited by 46
Multi-target approach to Alzheimer’s disease prevention and treatment: antioxidant, anti-inflammatory, and amyloid- modulating mechanisms
Abbas, K., Mustafa, M., Alam, M., Habib, S., Ahmad, W., Adnan, M., Hassan, M. I., & Usmani, N. (2025) · Neurogenetics · doi:10.1007/s10048-025-00821-y · Cited by 48
2026 Alzheimer's disease facts and figures
(2026) · Alzheimer s & Dementia · doi:10.1002/alz.71345 · Cited by 69
What is Alzheimer's disease? An analysis of nosological perspectives from the 20th and 21st centuries
Villain, N., & Michalon, R. (2024) · European Journal of Neurology · doi:10.1111/ene.16302 · Cited by 43
The vascular contribution of apolipoprotein E to Alzheimer’s disease
Chen, F., Zhao, J., Meng, F., He, F., Ni, J., & Fu, Y. (2024) · Brain · doi:10.1093/brain/awae156 · Cited by 39
Alzheimer disease seen through the lens of sex and gender
Castro‐Aldrete, L., Einsiedler, M., Martínková, J., Depypere, H. T., Ang, T. F. A., Mielke, M. M., Sindi, S., Eyre, H. A., Au, R., Dimech, A. S., et al. (2025) · Nature Reviews Neurology · doi:10.1038/s41582-025-01071-0 · Cited by 46
Self-citation
Exploring easily accessible neurophysiological biomarkers for predicting Alzheimer’s disease progression: a systematic review
Costanzo, M., Cutrona, C., Leodori, G., Malimpensa, L., D’Antonio, F., Conte, A., & Belvisi, D. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01607-4 · Cited by 40
Design and in vitro evaluation of curcumin-loaded PLGA nanoparticle-embedded sodium alginate/gelatin 3D printed scaffolds for Alzheimer's disease
Yekeler, H. B., Güler, E., Beato, P. S., Priya, S., Abobakr, F. K. M., Doğan, M., Üner, B., Kalaskar, D. M., & Çam, M. E. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.131841 · Cited by 37
Recent Progress in Nanomedicine for the Diagnosis and Treatment of Alzheimer’s Diseases
Yang, H., Tan, H., Wen, H., Xin, P., Liu, Y., Deng, Z., Xu, Y., Gao, F., Zhang, L., Ye, Z., et al. (2024) · ACS Nano · doi:10.1021/acsnano.4c11966 · Cited by 37
Association between migraine and Alzheimer’s disease: a nationwide cohort study
Kim, J., Ha, W., Park, S. H., Han, K., & Baek, M. S. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1196185 · Cited by 34
Evaluating p-tau217 and p-tau231 as Biomarkers for Early Diagnosis and Differentiation of Alzheimer’s Disease: A Narrative Review
Jarek, D. J., Mizerka, H., Nuszkiewicz, J., & Szewczyk‐Golec, K. (2024) · Biomedicines · doi:10.3390/biomedicines12040786 · Cited by 37
A Phase IIa clinical trial to evaluate the effects of anti-retroviral therapy in Alzheimer’s disease (ART-AD)
Sullivan, A. C., Zuniga, G., Ramirez, P., Fernandez, R. A., Wang, C., Li, J., Davila, L., Pelton, K., Gomez, S., Sohn, C., et al. (2025) · npj Dementia · doi:10.1038/s44400-024-00001-z · Cited by 33
Synbiotics of Lactobacillus suilingensis and inulin alleviates cognitive impairment via regulating gut microbiota indole‐3‐lactic acid metabolism in female AD mice
Yang, C., Sun, J., Li, L., Zheng, J. H., Wang, C., Zhao, Y., Yun, D., Jia, M., Wu, Z., Liang, H., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70406 · Cited by 38
Unraveling the intercellular communication disruption and key pathways in Alzheimer’s disease: an integrative study of single-nucleus transcriptomes and genetic association
Liu, A., Fernandes, B. S., Citu, C., & Zhao, Z. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01372-w · Cited by 34
Molecular Biomarkers of Neurodegenerative Disorders: A Practical Guide to Their Appropriate Use and Interpretation in Clinical Practice
Agnello, L., Gambino, C. M., Ciaccio, A. M., Masucci, A., Vassallo, R., Tamburello, M., Scazzone, C., Sasso, B. L., & Ciaccio, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25084323 · Cited by 38
Role of Calcitriol and Vitamin D Receptor (VDR) Gene Polymorphisms in Alzheimer’s Disease
Jeong, S. P., Sharma, N., & An, S. S. A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25094806 · Cited by 33
Effects of a multidomain intervention against cognitive decline on dementia risk profiles — Results from the AgeWell.de trial
Zülke, A. E., Pabst, A., Luppa, M., Oey, A., Weise, S., Fankhänel, T., Kosilek, R. P., Schillok, H., Brettschneider, C., Czock, D., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14097 · Cited by 32
Alzheimer’s Disease and Porphyromonas gingivalis: Exploring the Links
Shawkatová, I., Ďurmanová, V., & Javor, J. (2025) · Life · doi:10.3390/life15010096 · Cited by 35
Rethinking the detection and diagnosis of Alzheimer’s disease: Outcomes of a European Brain Council project
Dumas, A., Destrebecq, F., Esposito, G., Suchoňová, D., & Frederiksen, K. S. (2023) · Aging Brain · doi:10.1016/j.nbas.2023.100093 · Cited by 31
Nanotechnology in the diagnostic and therapy for Alzheimer's disease
Panghal, A., & Flora, S. J. S. (2024) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2024.130559 · Cited by 31
Cognitive synaptopathy: synaptic and dendritic spine dysfunction in age-related cognitive disorders
Barrantes, F. J. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1476909 · Cited by 37
Clinically Accurate Diagnosis of Alzheimer's Disease via Single‐Molecule Bioelectronic Label‐Free Profiling of Multiple Blood Extracellular Vesicle Biomarkers
Zheng, J., Jiang, X., Bai, S., Lai, M., Yu, J., Chen, M., Zhou, R., Jia, Y., Yan, H., Liang, Z., et al. (2025) · Advanced Materials · doi:10.1002/adma.202505262 · Cited by 32
Domino-like effect of C112R mutation on ApoE4 aggregation and its reduction by Alzheimer’s Disease drug candidate
Nemergut, M., Marques, S. M., Uhrik, L., Vanova, T., Nezvedova, M., Gadara, D. C., Jha, D., Tulis, J., Novakova, V., Planas-Iglesias, J., et al. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00620-9 · Cited by 30
Estimates of Current Capacity for Diagnosing Alzheimer's Disease in Sweden and the Need to Expand Specialist Numbers
Mattke, S., Gustavsson, A., Jacobs, L., Kern, S., Palmqvist, S., Eriksdotter, M., Skoog, I. G., Winblad, B. G., Wimo, A. B., & Jönsson, L. (2023) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2023.94 · Cited by 29
Self-citation
Elucidating the Role of Lipids in the Aggregation of Amyloidogenic Proteins
Kurouski, D. (2023) · Accounts of Chemical Research · doi:10.1021/acs.accounts.3c00386 · Cited by 31
APOE ε4 gene dose effect on imaging and blood biomarkers of neuroinflammation and beta-amyloid in cognitively unimpaired elderly
Snellman, A., Ekblad, L. L., Tuisku, J., Koivumäki, M., Ashton, N. J., Lantero‐Rodriguez, J., Karikari, T. K., Helin, S., Bucci, M., Löyttyniemi, E., et al. (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01209-6 · Cited by 31
APOE Peripheral and Brain Impact: APOE4 Carriers Accelerate Their Alzheimer Continuum and Have a High Risk of Suicide in PM2.5 Polluted Cities
Calderón‐Garcidueñas, L., Hernández-Luna, J., Aiello-Mora, M., Brito-Aguilar, R., Evelson, P., Villarreal-Ríos, R., Torres‐Jardón, R., Ayala, A., & Mukherjee, P. S. (2023) · Biomolecules · doi:10.3390/biom13060927 · Cited by 28
Thirty Risk Factors for Alzheimer’s Disease Unified by a Common Neuroimmune–Neuroinflammation Mechanism
Weaver, D. F. (2023) · Brain Sciences · doi:10.3390/brainsci14010041 · Cited by 34
Predicting Cognitive Decline in Amyloid-Positive Patients With Mild Cognitive Impairment or Mild Dementia
van der Veere, P. J., Hoogland, J., Visser, L. N. C., van Harten, A. C., Rhodius‐Meester, H. F. M., Sikkes, S. A. M., Venkatraghavan, V., Barkhof, F., Teunissen, C. E., van de Giessen, E., et al. (2024) · Neurology · doi:10.1212/wnl.0000000000209605 · Cited by 33
CD103–CD8+ T cells promote neurotoxic inflammation in Alzheimer’s disease via granzyme K–PAR-1 signaling
Terrabuio, E., Pietronigro, E. C., Bani, A., Bianca, V. D., Laudanna, C., Rossi, B., Finotti, G., Santos-Lima, B., Zenaro, E., Turano, E., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-62405-6 · Cited by 33
Among Gerontogens, Heavy Metals Are a Class of Their Own: A Review of the Evidence for Cellular Senescence
Vielee, S. T., & Wise, J. P. (2023) · Brain Sciences · doi:10.3390/brainsci13030500 · Cited by 31
Pathophysiological Association of Alzheimer’s Disease and Hypertension: A Clinical Concern for Elderly Population
Yao, Q., Jiang, K., Lin, F., Zhu, T., Khan, N. H., & Jiang, E. (2023) · Clinical Interventions in Aging · doi:10.2147/cia.s400527 · Cited by 31
Disease severity and mortality in Alzheimer's disease: an analysis using the U.S. National Alzheimer’s Coordinating Center Uniform Data Set
Crowell, V., Reyes, A., Zhou, S. Q., Vassilaki, M. E., Gsteiger, S., & Gustavsson, A. (2023) · BMC Neurology · doi:10.1186/s12883-023-03353-w · Cited by 31
Self-citation
Microglial immunometabolism endophenotypes contribute to sex difference in Alzheimer's disease
Hou, Y., Caldwell, J., Lathia, J. D., Leverenz, J. B., Pieper, A. A., Cummings, J. L., & Cheng, F. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13546 · Cited by 29
RETRACTED: Parthenolide alleviates cognitive dysfunction and neurotoxicity via regulation of AMPK/GSK3β(Ser9)/Nrf2 signaling pathway
Sun, J., Li, L., Li, X., Chen, F., She, L., Tang, H., Zeng, Y., Duan, Y., Li, L., Wang, W., et al. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115909 · Cited by 28
Retracted
Structure characterisation of polysaccharides purified from Boletus aereus Bull. and its improvement on AD-like behaviours via reliving neuroinflammation in APP/PS1 mice
Zhu, Y., Li, L., Jin, X., Li, Z., Wang, C., Teng, L., Li, Y., Zhang, Y., & Wang, D. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.128819 · Cited by 29
Repressor Element-1 Binding Transcription Factor (REST) as a Possible Epigenetic Regulator of Neurodegeneration and MicroRNA-Based Therapeutic Strategies
Nassar, A., Satarker, S., Gurram, P. C., Upadhya, D., Fayaz, S., & Nampoothiri, M. (2023) · Molecular Neurobiology · doi:10.1007/s12035-023-03437-1 · Cited by 27
A Literature Review on the Burden of Alzheimer’s Disease on Care Partners
Frederiksen, K. S., Lanctôt, K. L., Weidner, W. S., Hahn‐Pedersen, J. H., & Mattke, S. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-230487 · Cited by 34
Charting Alzheimer’s Disease and Dementia: Epidemiological Insights, Risk Factors and Prevention Pathways
Contador, I., Buch-Vicente, B., del Ser, T., Velasco, S. L., Villarejo‐Galende, A., Benito‐León, J., & Bermejo‐Pareja, F. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13144100 · Cited by 31
Phosphorylated tau in cerebrospinal fluid-derived extracellular vesicles in Alzheimer’s disease: a pilot study
Sattarov, R., Havers, M., Orbjörn, C., Stomrud, E., Janelidze, S., Laurell, T., & Mattsson, N. (2024) · Scientific Reports · doi:10.1038/s41598-024-75406-0 · Cited by 29
Altered T-cell reactivity in the early stages of Alzheimer's disease
Rickenbach, C., Mallone, A., Häusle, L., Frei, L., Seiter, S., Sparano, C., Kirabali, T., Blennow, K., Zetterberg, H., Ferretti, M. T., et al. (2025) · Brain · doi:10.1093/brain/awaf167 · Cited by 27
Self-citation
Association and multimodal model of retinal and blood-based biomarkers for detection of preclinical Alzheimer’s disease
Ravichandran, S., Snyder, P. J., Alber, J., Murchison, C., Chaby, L. E., Jeromin, A., & Arthur, E. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01668-5 · Cited by 28

Authors: Gustavsson, A., Norton, N., Fast, T., Frölich, L., Georges, J., Holzapfel, D., Kirabali, T., Krolak‐Salmon, P., Rossini, P. M., Ferretti, M. T., Lanman, L., Chadha, A. S., & van der Flier, W. M.
Affiliations: Karolinska Institutet (SE)
Quantify Research (Sweden) (SE)
Heidelberg University (DE)
Alzheimer Europe (LU)
CEO Initiative on Alzheimer's Disease Philadelphia USA
Biogen (Switzerland) (CH)
Hospices Civils de Lyon (FR)
Università Cattolica del Sacro Cuore (IT)
Women's Brain Project (CH)
F. Hoffmann-La Roche AG (CH)
Alzheimer Center Amsterdam Department of Neurology Department of Epidemiology and Data Science Amsterdam Neuroscience Amsterdam UMC, Vrije Universiteit Amsterdam Amsterdam the Netherlands
Corresponding author: Gustavsson, Anders
ORCID: Gustavsson, Anders
Norton, Nicholas
Georges, Jean
Kirabali, Tunahan
Krolak‐Salmon, Pierre
Rossini, Paolo M.
Ferretti, Maria Teresa
Chadha, Antonella Santuccione
Venue: Alzheimer's & Dementia
Publisher: Wiley
Published: 2022-06-02
Volume: 19
Issue: 2
Pages: 658-670
ISSN: 1552-5260 (ISSN-L)
1552-5279
DOI: 10.1002/alz.12694
OpenAlex: W4281674975
Cited by: 895
References: 62
Citations by year: 2026: 207 · 2025: 323 · 2024: 236 · 2023: 114 · 2022: 15
FWCI: 112.57
Type: journal article
Language: en
Open access: hybrid
doi.org
Licence: cc-by-nc
creativecommons.org/licenses/by-nc/4.0/ (vor)
Locations: Alzheimer s & Dementia (publishedVersion, cc-by-nc)
PubMed (publishedVersion)
Pure Amsterdam UMC (publishedVersion, other-oa)
Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion, other-oa)
Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
Funders: F. Hoffmann-La Roche
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Health Sciences › Medicine › Complementary and alternative medicine › Medicinal Plants and Neuroprotection
Keywords: Alzheimer's disease, Alzheimer's disease continuum
MeSH terms: Alzheimer Disease, Humans, Biomarkers, Prevalence, Prodromal Symptoms

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Global estimates on the number of persons across the Alzheimer's disease continuum

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks